Short-term cardiovascular effects of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder

CNS Spectrums

Volumn 10, Issue 10 SUPPL. 15, 2005, Pages 31-38

  Connor, Daniel F ^a   Spencer, Thomas J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; MIXED AMPHETAMINE SALT; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; EXTENDED RELEASE FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THYROIDITIS; TITRIMETRY; VIRAL THYROIDITIS; VIRUS INFECTION;

EID: 27244437985     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900014127     Document Type: Article

References (26)

1. American Association for Child and Adolescent Psychiatry. Children with oppositional defiant disorder. Facts for families. No. 72. Available at: http://www.aacap. org/publications/factsFam/72.htm. Accessed April 7, 2005.
2. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. Arch Gen Psychiatry. 1988;45:1120-1126.
3. Bird HR, Madelyn SG, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry. 1993;32:361-368.
4. Szatmari P, Boyle M, Offord DR. ADHD and conduct disorder: degree of diagnostic overlap and differences among correlates. J Am Acad Child Adolesc Psychiatry. 1989;28:865-872.
5. Greene RW, Biederman J, Zerwas S, et al. Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Amn J Psychiatry. 2002;159:1214-1224.
6. Mannuzza S, Klein RG, Abikoff H, et al. Significance of childhood conduct problems to later development of conduct disorder among children with ADHD: a prospective follow-up study. J Abnorm Child Psychol. 2004;32:565-573.
7. Abikoff HA, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:802-811.
8. Greene RW, Ablon JS, Goring JC, et al. Effectiveness of collaborative problem solving in affectively dysregulated children with oppositional-defiant disorder: initial findings. J Consult Clin Psychol 2004;72:1157-1164.
9. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
10. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
11. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40:147-158.
12. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999;99:979-982.
13. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry. 2001;40:525-529.
14. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:409-432.
15. Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1992;2:279-290.
16. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22:1107-1131.
17. Wilens TE, Biederman J, Lerner M, and the Concerta® Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder. Results from a one-year follow-up study. J Clin Psychopharmocol. 2004;24:36-41.
18. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147. In press.
19. Spencet TJ, Abikoff HB, Connor DF, et al. The safety and efficacy of Adderall XR (mixed amphetamine salts extended release) in the management of oppositional defiant disorder (ODD) in school-age children and adolescents. Clin Ther. 2005. In press.
20. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
21. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-aged Children-Present and Lifetime version (K-SADS-PL). J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
22. Bazett H. An analysis of time relations of electrocardiogram. Heart. 1920;7:353-370.
23. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. 1997. Cary, NC: SAS Institute.
24. Committee for Proprietary Medicinal Products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London, UK: the European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; December 17,1997. Report No. CPMP/986/96.
25. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactiyity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113:e206-e216.
26. Adderall XR (package insert). Shire US Inc.: Wayne, PA; 2004.